Efsubaglutide Alfa: Innogen’s $1 Billion GLP-1 Deal Takes China’s Long-Acting Drug to Emerging Markets
Innogen has licensed its China-approved GLP-1 efsubaglutide alfa to Arcera for Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion.
